Metraipolis › archive › dc_64afefa0c22e

Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan — Europe PMC PMID:40914783

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40914783
DOI
10.1007/s10147-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-11-10T02:29:29.635Z
SHA-256 of the archived text
30783e31bc993a3c869007711e1a395a891a8e8a868d26c64bb5bc2b4fcf2757
Stable URL of this page
https://metraipolis.com/documento/dc_64afefa0c22e

How to cite

Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan — Europe PMC PMID:40914783 — Europe PMC (en), https://europepmc.org/article/MED/40914783 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_64afefa0c22e (Metraipolis archive dc_64afefa0c22e, sha256 30783e31bc993a3c869007711e1a395a891a8e8a868d26c64bb5bc2b4fcf2757)
BibTeX
@misc{dc64afefa0c22e,
  title = {Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan — Europe PMC PMID:40914783},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40914783},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_64afefa0c22e; sha256 30783e31bc993a3c869007711e1a395a891a8e8a868d26c64bb5bc2b4fcf2757},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40914783. Agents can read the archived copy with the MCP tool read_document.